Skip to main content
. 2019 Mar 23;8(3):280. doi: 10.3390/cells8030280

Figure 7.

Figure 7

DNP as a Broad-Spectrum Treatment. DNP (MP101) or the prodrug of DNP (MP201) has been tested in disease models of acute and chronic studies with a known and unknown genetic cause that representing pediatric, adult and elderly indications with statistically positive outcomes. The indications also present diseases of neuromuscular disorders, development, neurodegeneration, autoimmune, metabolic and trauma. The future will help to determine the limitations of the pharmacology, but given the findings, it appears that DNP may be a broad-spectrum treatment to many disorders.